<DOC>
	<DOCNO>NCT00384228</DOCNO>
	<brief_summary>This study investigate nilotinib provide improved safety efficacy profile see patient receive Imatinib .</brief_summary>
	<brief_title>A Phase l/ll Study AMN107 Adult Patients With Glivec-intolerant CML Relapsed-refractory Ph+ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Diagnosed Ph+ ALL either relapse refractory standard therapy Diagnosed CML blast crisis accelerate phase chronic phase resistant intolerant imatinib Performance status normal ambulatory capable selfcare Exclusion Criteria A history significant serious uncontrolled cardiovascular disease Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption nilotinib Patients pregnant breast feeding , adult reproductive potential employ effective method birth control Cytopathologically confirm CNS infiltration NB : absence suspicion CNS involvement , lumbar puncture require Impaired cardiac function , include one follow LVEF &lt; 45 % determined echocardiogram Complete leave bundle branch block Use cardiac pacemaker ST depression &gt; 1mm 2 lead and/or Twave inversion 2 contiguous lead Congenital long QT syndrome History presence significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 480 msec screen ECG ( use QTcF formula ) Right bundle branch block plus leave anterior hemiblock , bifascicular block Myocardial infarction within 3 month prior start AMN107 Uncontrolled angina pectoris Other clinically significant heart disease ( e.g. , congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption AMN107 ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Use therapeutic warfarin Acute chronic liver renal disease consider unrelated tumor ( e.g. , hepatitis , cirrhosis , renal insufficiency , etc . ) Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol Treatment hematopoietic colonystimulating growth factor ( e.g. , GCSF ) ≤ 1 week prior start study drug . Patients currently receive treatment medication list ( cf . Posttext suppl . 5 ) either discontinue switched different medication prior start study drug . The medication list ( cf . Posttext suppl . 5 ) potential prolong QT interval . Patients receive chemotherapy ≤ 1 week within 5 halflives last dose chemotherapy ( 6 week nitrosurea mitomycinC ) prior start study drug recover side effect therapy . Hydroxyurea permit investigator 's discretion prior enrollment . Patients receive Glivec® ≤ 1 week recover side effect therapy . Patients receive immunotherapy ≤ 1 week prior start study drug recover side effect therapy . Patients receive investigational drug ( exclude STI571/Glivec ) ≤ 4 week investigational cytotoxic agent within 1 week ( within 5 halflives previous investigational cytotoxic agent ) prior start study drug recover side effect therapy . Patients receive wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug recover side effect therapy . Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy . Patients pregnant breast feeding , adult reproductive potential employ effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 48 hrs prior administration AMN107 ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) Patients history another primary malignancy currently clinically significant currently require active intervention . Patients unwilling unable comply protocol Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>